Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Shorter Booster Interval for All Citizens Difficult: Health Minister
December 8, 2021
- Written Pledge Rule on Generic Listing to Continue after 2021; Companies Feel Pressure for Stable Supplies
December 7, 2021
- BMS’ Second CAR-T Therapy Ide-Cel in Line for Approval in January
December 7, 2021
- MHLW to Prepare List of Priority Infectious Diseases by March-End, Set Up Study Group in December
December 7, 2021
- Japan Panels Agree to Add Myocarditis as ADRs for Pfizer, Moderna Vaccines
December 6, 2021
- 2 mRNA Jabs Ordered to Add Myocarditis to ADR List: Label Revision
December 6, 2021
- Panel OKs Outline of Emergency Approval System Based on “Presumed” Efficacy
December 6, 2021
- MHLW Issues Revised Drug Distribution Guidelines; Effective January 1
December 6, 2021
- MOF Panel’s Budget Proposal Pushes Macroeconomic Indexing, No Adjustment Rate
December 6, 2021
- Pharma Industry Wants Grace Period of at Least 5 Years for Spillover Exclusion Rule
December 6, 2021
- Japan Generic Share at 79% in September 2021: Drug Price Survey
December 6, 2021
- Average NHI-Market Price Gap of Listed Drugs at 7.6%: MHLW
December 3, 2021
- Amgen’s KRAS Inhibitor, MSD’s Cough Drug Sail through PAFSC, January Approval Likely
December 3, 2021
- 70% of Pharmacies Procured Alternative Products due to Generic Scandals in FY2020: Chuikyo Survey
December 3, 2021
- Chuikyo Defers Coverage for SaMD for Breast Cancer Recurrence Risk Assessment; Software Remains Incomplete
December 3, 2021
- MHLW Eyes Emergency Approval System Based on “Presumed” Efficacy
December 2, 2021
- Chuikyo OKs 2022 Reform Outline for Cost-Effectiveness Assessment System
December 2, 2021
- Chuikyo Reps Acknowledge Need for Adjustment Rate: 2022 Price Revision
December 2, 2021
- Chuikyo Members Call for Restrictions in Re-Pricing Exclusions from Spillover Rule
December 2, 2021
- ICH Adopts E8, M8 Guidelines; 3 Topics Reach Step 2
December 2, 2021
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…